Marksans Pharma Q4FY26: record profits, cash strength, and an OTC-led growth engine

Marksans Pharma ended FY26 with its strongest set of annual numbers so far, and it did it while staying net cash positive. Management called FY26 a milestone year, with total income reaching ₹3,033 crore and EBITDA rising to ₹601 crore at a 20.4% margin. Profit after tax came in at ₹420 crore. In Q4FY26, the momentum accelerated as total income reached ₹891 crore, EBITDA rose to ₹195 crore, and PAT climbed to ₹149 crore. The quarter stood out for both growth and profitability, with EBITDA margin at 22.8% and net margin at 16.7%.

The story behind the numbers is a familiar Marksans pattern, but with higher scale. Growth was driven by a steady cadence of launches across markets, deeper retailer relationships in the US consumer healthcare channel, and a sharp recovery in the UK. Australia added a new dimension as the company moved from an OTC-heavy base to launching branded prescription products through Nova Pharma. Alongside growth, the balance sheet stayed strong. Marksans closed FY26 with a cash balance of about ₹990 crore and generated ₹458 crore of operating cash during the year. Capex moderated to ₹131 crore, with management indicating the major capex cycle is nearly complete.

In short, FY26 combined execution and financial discipline. Revenue growth was healthy, margins stayed resilient, and the company retained the flexibility to pursue selective inorganic expansion, especially in Europe.

FY26 at a glance: growth with stable margins

FY26 growth was broad-based, but not uniform. Total income increased 12.8% YoY to ₹3,033 crore, and EBITDA grew at the same pace to ₹601 crore. Gross profit rose 13.2% to ₹1,674 crore, with gross margin moving slightly higher to 56.7% from 56.4%. Management attributed this to softer raw material prices and a better product mix, supported by favorable currency movement.

Net profit growth was positive but slower than operating profit, with PAT rising 9.8% to ₹420 crore. The net margin eased to 13.8% from 14.2%, which suggests that while the operating engine is scaling, non-operating lines such as taxes, depreciation, and finance costs continue to matter at this higher revenue base. Depreciation and amortization increased to ₹98.6 crore in FY26 from ₹83.4 crore in FY25, consistent with a business that has expanded capacity and completed a capex cycle.

The balance sheet shows what management has been prioritizing through this growth phase. Marksans ended FY26 with total equity of ₹3,053 crore and total assets of ₹3,861 crore. Cash and cash equivalents were ₹634 crore, and additional bank balances were ₹356 crore, taking the cash balance referenced by management to about ₹990 crore at year end. Inventories stood at ₹972 crore and trade receivables at ₹645 crore, reflecting the working-capital intensity of supplying large geographies and multiple product formats. Management indicated a working capital cycle of about 138 days for FY26.

Two operating signals in FY26 stand out for investors tracking repeatability. First, the company continued investing in new products. R and D spend was ₹89 crore, about 3.0% of consolidated revenue. Second, cash conversion remained solid. Cash generated from operations was ₹458 crore, supporting both capex and the maintenance of a net cash position.

Q4FY26: a quarter that tied the narrative together

Q4FY26 was where several moving parts aligned. Operating revenue rose 20.8% YoY to ₹856 crore and 13.5% QoQ from ₹754 crore. EBITDA rose 54.0% YoY to ₹195 crore and 21.6% QoQ. PAT increased 64.3% YoY to ₹149 crore and 31.1% QoQ.

Margin performance explains why the quarter stood out. EBITDA margin expanded to 22.8% from 17.9% in Q4FY25, an improvement of 491 basis points. Sequentially, EBITDA margin improved 152 basis points from 21.3% in Q3FY26. Management cited operating leverage and tight cost control as the key drivers.

At the gross profit level, the picture was more mixed. Gross margin was 54.4% in Q4FY26 versus 58.1% in Q3FY26, a decline of 372 basis points sequentially. Management highlighted rising input costs due to geopolitical tensions as a factor. Still, EBITDA margin expansion suggests that the company offset part of the gross pressure through operating discipline and scale.

Other income also mattered in Q4. Other income rose to ₹35 crore in Q4FY26 from ₹20 crore in Q3FY26 and ₹15 crore in Q4FY25, with management pointing to favorable forex gains. This helped PAT grow faster than EBITDA in the quarter.

The quarterly trend line across FY26 reinforces the improvement. Revenue moved from ₹620 crore in Q1FY26 to ₹856 crore in Q4FY26. EBITDA grew from ₹100 crore in Q1 to ₹195 crore in Q4. Net income rose from ₹58 crore in Q1 to ₹149 crore in Q4. For investors, this is useful context because it shows that Q4 was not an isolated spike. It was the peak of a year that strengthened as execution improved.

Geography: the US leads, the UK recovers, Australia adds a new layer

Marksans is still anchored by the US and North America, which contributed about 52% of FY26 revenue. FY26 revenue in the region increased 24% to ₹1,533 crore, rising from ₹635 crore in FY22. The company described the region as its largest market, built around consumer healthcare and OTC store brands. It manufactured and distributed 100 plus products, launched 112 new SKUs in FY26, and reported 51 products in the pipeline.

Notably, US quarterly revenue in Q4FY26 was ₹406 crore, up 23.6% YoY but down 1.5% QoQ. Management described the sequential decline as timing-related, driven by order dispatch scheduling rather than demand weakness. This matters because investors often react to a single quarter. The company’s framing is that the order book remains healthy, and the larger trend is still upward.

The UK and Europe, the second-largest region at about 34% of FY26 revenue, was the softer spot for the full year but the strongest highlight in Q4. FY26 revenue was ₹1,015 crore, down 1.4% YoY. Management attributed the dip to a seasonally weak Q1 and high single-digit price erosion in select UK products, followed by a recovery through the second half. Q4FY26 revenue reached ₹308 crore, up 12.3% YoY and 19.2% QoQ, and management described it as the highest-ever quarterly revenue for the region. Importantly, it stated that price erosion in the UK products stabilized in Q4FY26.

Australia and New Zealand delivered the sharpest quarterly inflection. FY26 revenue grew 19.9% YoY to ₹303 crore. In Q4FY26, revenue surged to ₹123 crore, up 61.3% YoY and 100.9% QoQ. Management connected this step-up to new launches, healthy volume growth, and seasonality, noting that Q4 is structurally the strongest quarter in Australia due to the winter cold and flu cycle.

But the strategic significance is not just the seasonal demand. Marksans expanded the region’s profile by launching a branded prescription division under Nova Pharma and introducing 11 Rx brands in FY26. This is a shift from an historically OTC-only model in that geography, and it adds optionality over time if execution stays consistent.

Rest of World remained small at about 3% of FY26 revenue and moved down in FY26. Revenue was ₹99 crore, down 4.1% YoY, with management highlighting geopolitical tensions, macro volatility, and elevated payment risks in select markets. Q4FY26 revenue in RoW was ₹19 crore, down 35.7% YoY and 15.9% QoQ, impacted by disruptions and logistics constraints.

Strategy and execution: why the model is holding up

Marksans’ presentation makes its positioning clear. It is aligning the company with a structural shift toward consumer healthcare and OTC store brands. Management cited IQVIA estimates that the global OTC market size is expected to be $215 billion in 2026, with Rx-to-OTC switches supporting growth. The company’s own data shows how central this has become. OTC accounted for 80% of FY26 revenue mix, with Rx at 20%. Within OTC, the FY26 revenue split was presented as about 85% store brands and 15% own labels.

This focus explains the company’s operational choices. It continues to build a large SKU base and a launch engine across markets. In FY26 it launched 112 new SKUs in the US and expanded regulatory filings and approvals in the UK and Europe. For the UK, the company highlighted 18 products approved and 30 filings done in FY26, with 24 products awaiting approval as of 31 March 2026. It also indicated a longer arc pipeline, stating that 200 plus products are planned to be filed over the next four years.

Capacity scale is the second pillar. Marksans reported total capacity of 26 billion units per annum across manufacturing facilities, with plants in the US, UK, and Goa. It also outlined plans to expand Indian capacity to 16 billion units per annum, including the acquired Goa unit intended to manufacture tablets, ointments, liquids, and creams. The company sees this capacity as a lever for operating leverage as volumes grow.

The third pillar is capital discipline and optionality for acquisitions. With a cash balance of about ₹990 crore, net cash status sustained for over five years, and a CARE rating of AA- (stable) and A1+ for short term, management positioned the balance sheet as a tool for calibrated inorganic growth. It specifically stated it is evaluating acquisitions in the Europe region for front-end presence.

Still, risks are not absent. Management flagged emerging input cost pressures and linked part of the quarterly gross margin movement to geopolitical tensions. The RoW performance also shows how external disruptions can affect execution through logistics and payment cycles. For investors, the key question is whether Marksans can protect margins through mix, scale, and cost control if input inflation persists.

Takeaways for investors

Marksans Pharma’s FY26 and Q4FY26 performance points to a company that has moved into a higher scale band without losing operational control. The company delivered total income of ₹3,033 crore and EBITDA of ₹601 crore, while closing the year with about ₹990 crore of cash. Q4FY26 strengthened the narrative by combining 20.8% YoY revenue growth with a sharp rise in profitability, taking EBITDA margin to 22.8%.

The geographic mix remains anchored in the US and North America, where the store-brand OTC model continues to scale and the launch engine remains active. The UK and Europe are in a repair phase on an annual basis, but Q4 showed stabilization and record quarterly revenue, which may matter more for sentiment and near-term trend tracking. Australia and New Zealand looks like the next layered growth story, with a visible inflection in Q4 and the start of an Rx branded portfolio under Nova Pharma.

The theme that runs through the presentation is disciplined execution. The company highlights that it achieved its stated guidance of ₹3,000 crore total income, sustained EBITDA margins in the 19 to 20% range for the full year, maintained a net cash balance sheet, and kept capex disciplined. If input costs remain volatile, the next test will be whether operating leverage and mix can keep margins resilient. But with a strong cash position, a broad pipeline, and expanding front-end presence, Marksans enters FY27 with more options than it had a few years ago.